USPTO serial 97596410
MOPED
Reviewed by CopyMark Law Group
Status 734Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- PORTARO, ALEXANDRA J
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with MOPED?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $648*
Plus Government fees of $300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joyce M. Ferraro
Joyce M. Ferraro FROSS ZELNICK LEHRMAN & ZISSU, P.C.151 WEST 42ND STREET, 17TH FLOORNEW YORK, NY 10036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable computer software for drug discovery, screenings, and providing pharmaceuticals; downloadable computer software for use to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; downloadable computer software for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry, clinical trial management and patient engagement | ACTIVE | — |
| 042 | Drug discovery services; DNA and protein screening for scientific research purposes; Platform as a service (PAAS) featuring computer software platforms for drug discovery, screenings, and providing pharmaceuticals; Scientific and technological services and research and design, namely, research and design in the field of drug discovery and DNA and protein screening; Scientific research and development in the field of analysis of technical data by computers; pharmaceutical drug discovery services; research and development in the pharmaceutical and biotechnology fields; drug discovery services and research and development in the pharmaceutical drug use field; design and development of pharmaceutical preparations and medicines; scientific research and development in the field of drug discovery; scientific research and development in the nature of conducting scientific and pharmaceutical research and data analysis to screen for and identify molecular interactions, compounds and detect toxicity; providing scientific, pharmaceutical and agrochemical database research services; scientific research and development in the nature of scientific and pharmaceutical artificial intelligence research services to identify molecules and compounds for drug discovery and chemical development; scientific research and development in the nature of bioinformatics services for using the combination of biology, computer science, information engineering, mathematics and statistics to analyze and interpret biological data; scientific research and development in the nature of computer assisted molecule design; scientific research and development in the nature of identification of biological targets, networks and pathways; biological research and analysis; pharmaceutical research and development services; computer aided diagnostic and DNA and protein screening services for scientific research purposes; scientific research and development in the nature of contract research services in support of scientific research and development of pharmaceutical preparations; Software as a service (SaaS) services featuring software to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; Software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; Software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of clinical trial management and patient engagement | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 18, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 18, 2026 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Sep 17, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 4, 2026 | EXT5 | SOU EXTENSION 5 FILED | — |
| Aug 4, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 12, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 12, 2026 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 12, 2026 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 12, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 31, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 30, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jul 30, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jul 30, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 3, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 24, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jan 23, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jan 23, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 12, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 12, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 12, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 12, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 13, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 19, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 19, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 29, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 14, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 14, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 14, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 14, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 14, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 5, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 5, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 5, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 7, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 7, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 7, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 29, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 4, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 22, 2022 | NWAP | NEW APPLICATION ENTERED | — |